Table 3.
Correlations in PD patients between 8-OHdG, 8-ISO, TAC, and MoCA scores with UPDRS scores and clinical disease duration.
| Association | LRRK2 PD | sPD |
|---|---|---|
| 8-OHdG vs. UPDRS Total score | -0.14 (0.56) | -0.18 (0.33) |
| 8-OHdG vs. UPDRS Part 3 score | -0.11 (0.65) | -0.22 (0.22) |
| 8-OHdG vs. clinical duration | -0.12 (0.62) | -0.39 (0.03) |
| 8-ISO vs. UPDRS Total score | 0.10 (0.69) | 0.17 (0.35) |
| 8-ISO vs. UPDRS Part 3 score | 0.14 (0.56) | 0.10 (0.61) |
| 8-ISO vs. clinical duration | 0.24 (0.32) | -0.24 (0.20) |
| TAC vs. UPDRS Total score | -0.33 (0.17) | -0.41 (0.02) |
| TAC vs. UPDRS Part 3 score | -0.30 (0.21) | -0.20 (0.29) |
| TAC vs. clinical duration | -0.11 (0.64) | -0.37 (0.04) |
| MoCA score vs. UPDRS Total score | -0.30 (0.22) | -0.49 (0.005) |
| MoCA score vs. UPDRS Part 3 score | -0.27 (0.27) | -0.33 (0.07) |
| MoCA score vs. clinical duration | -0.38 (0.11) | -0.18 (0.33) |
For the two groups of PD patients, the correlations (Spearman rho values) of 8-OHdG, 8-ISO, TAC, and MoCA scores with UPDRS scores and duration of clinical disease are shown, with p-values in parentheses. TAC was negatively correlated with UPDRS Total scores in both PD groups. 8-OHdG and TAC were negatively correlated with clinical duration in sPD patients, and MoCA scores were negatively associated with UPDRS scores in this group. (8-OHdG, 8-hydroxy-2′-deoxy-guanosine; 8-ISO, 8-isoprostane; TAC, total antioxidant capacity; LRRK2 PD, Parkinson’s disease patients with LRRK2 mutations; sPD, sporadic Parkinson’s disease patients; LRRK2 CTL, healthy control subjects with LRRK2 mutations; CTL, healthy control subjects without known PD-associated mutations; MoCA, Montreal Cognitive Assessment; UPDRS, Unified Parkinson’s Disease Rating Scale).